Form 4 for PCVX Vaxcyte, Inc.
Accepted 2022-08-05 00:00:00 ET · period of report 2022-08-04 · accession 0001209191-22-044659 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2022-08-05 | 2022-08-04+ | PCVX | Fairman Jeff | VP, Research | S - Sale | $25.57 | -15.0K | 306.2K | -5% | -$383.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-04 | S | D | 10,000 | $25.50 | 311,227 | I By Fairman Family Trust | — | — | |
| 2 | Common | Common Stock | 2022-08-05 | S | D | 5,000 | $25.70 | 306,227 | I By Fairman Family Trust | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $25.50 to $26.035. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |